Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Multiple 30-Month Stays Remain Possible Under Waxman/Hatch Reforms

Executive Summary

Multiple 30-month stays on abbreviated new drug applications are still an option in some cases, an FDA 1draft guidance says

You may also be interested in...



Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices

During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.

Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices

During Senate Health, Education, Labor and Pensions Committee hearing on the former Eli Lilly executive's nomination for HHS Secretary, Alex Azar said department should consider whether REMS still necessary upon generic entry.

Boniva Gets A Second, Truncated 30-Month Stay

Orchid's revised patent certification against the osteoporosis drug ibandronate allows Roche to block approval until March 2012.

Related Content

UsernamePublicRestriction

Register

PS044944

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel